Our News

See The Latest PharmaEssentia News

Our News

See The Latest PharmaEssentia News

Our innovation

Our research and development team has created a novel pegylation technology platform with the potential to treat a variety of hematologic cancers.

PharmaEssentia USA draws on the scientific capabilities of the PharmaEssentia Innovation Research Center (PIRC), part of PharmaEssentia Corporation, whose R&D advances support and enhance our efforts in the United States.

Learn About Our R&D

Our focus:
Myeloproliferative Neoplasms

We are committed to being a leader in myeloproliferative neoplasms (MPNs), including an approved product for adults with polycythemia vera (PV) and ongoing clinical programs for essential thrombocythemia (ET) early myelofibrosis.

Explore Our Science

Real patients. Real progress.

Deb thought she was the picture of health before her diagnosis, but in hindsight the signs and symptoms had likely been there for years. However, she chose to not let PV define her and has learned to cope with her disease through the power of music.

Read Our Patient Stories

Join our team

Want to make a positive impact on the lives of others while expanding your own possibilities?

Explore Our Opportunities